Loading
Life sciences · Phase 2 Trial
ClinicalTrials.gov · October 9, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Phase 2 Trial.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT04153136). This is a study registration, not published results. Lead sponsor: Massachusetts General Hospital. Recruitment status: COMPLETED. Phase: PHASE2. Study type: INTERVENTIONAL. Enrollment: 39 participants (ACTUAL). Conditions: HIV/AIDS, Heart Failure With Preserved Ejection Fraction. Interventions: DRUG: Sacubitril-Valsartan 49-51Mg Oral Tablet; DRUG: Placebo oral tablet. Primary outcome measures: Myocardial Inflammation/Fibrosis , Baseline and 6 months; Myocardial Dysfunction , Baseline and 6 Months. Brief summary: Persons with HIV, even those well-treated, are at increased risk for heart disease when compared to the general population. Two hormones called aldosterone and brain natriuretic peptide (BNP), which have been shown to be abnormal in HIV, may be associated with inflammation as well as early changes in structure and function of the heart. This study is being conducted to evaluate whether therapies to block aldosterone and increase BNP levels may reduce the burden and progression of heart failure to improve cardiovascular health.